Neurofibrillary tangles (NFTs) in AD brain are consist of paired helical filaments (PHFs), which are mainly composed of hyperphosphorylated tau protein
(Maccioni et al.
The use of heavy isotope-labeled tau protein
as an IS, added at the very beginning of the procedure before immunoaffinity enrichment, was required to account for variability throughout sample processing.
In many forms of dementia, such as Alzheimer's disease and chronic traumatic encephalopathy caused by multiple concussions, the tau protein
starts behaving badly and instead of performing its normal cellular functions, it begins accumulating and interfering with cell-to-cell communications.
is responsible for the assembly of microtubules within the cell that form its structure.
Second, prior to the usage of diagnostic tools that helped identify amyloid beta and tau protein
in living patients (as opposed to postmortem), a diagnosis could not be considered definitive, limiting the utility of the test and thereby hindering the management of the disease.
is associated with the microtubules that form part of the cytoskeleton in neurons in the brain.
The animals had more amyloid-beta plaques, a higher load of abnormal tau protein
and more severe inflammation in their brains.
Chronic stress triggers the production of the insoluble tau protein
aggregates in the brain cells of mice -- the substance that leads to Alzheimer's disease.
They then compared tau protein
aggregates in the brains of these mice with a control group.
Neurofibrillary tangles, which are composed of abnormally phosphorylated tau protein
aggregates, appear as parallel, thickened fibrils that extend toward the apical dendrite of pyramidal neurons.
These first findings from the Domi-nantly Inherited Alzheimer Network (DIAN) study, a 6-year, cross-sectional, longitudinal study indicate that the use of PET and cerebrospinal fluid bio-markers of beta-amyloid and tau protein
may allow researchers to select enriched pools of subjects for the testing of potential drug treatments, and, someday, allow clinicians to target patients with incipient disease for preventive treatment, Dr.
The drug, rember, is the first to target the "tangles" of Tau protein
that develop in the brain with Alzheimer's, killing off cells needed for memory.